Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Heptares
Biotech
Nxera lays off staff, pivots pipeline in profitability push
Under the new plan, Nxera is focused on next-generation therapies for obesity, metabolic and endocrine disorders.
Nick Paul Taylor
Nov 17, 2025 9:44am
Boehringer pays €25M for option to Sosei’s schizophrenia drug
Mar 11, 2024 9:10am
GSK jilts Sosei, axing bowel disease drug amid immunology pivot
Nov 27, 2023 5:00am
AbbVie pays Sosei $40M to form neurological drug discovery pact
Aug 2, 2022 7:00am
Verily links up with Sosei Heptares for GPCR drug discovery
Jan 6, 2022 3:30pm
AbbVie dumps unwanted Sosei neuro pact from Allergan's past
Jan 5, 2021 9:42am
